Fucoxanthin Attenuates the Lipopolysaccharide‑induced Sepsis and Acute Lung Injury through the Inactivation of Nuclear Factor‑Kappa B Signaling Pathway

Objectives: The acute lung injury was a very severe health consequence and it was allied with the highest morbidity as well as mortality rate among the peoples. The acute lung injury can be induced through the various direct or indirect causative factors such as serious septic conditions, inflammation of the lung tissues, swelling of the lungs, injury of inhalation, pulmonary vasculitis, pancreatitis, and severe burnings which can lead to the unrestrained inflammation. Materials and Methods: The sepsis was a major clinical syndrome that can cause by severe infection or injury and it was distinguished by the response to the entire body inflammation. The current research work aimed to assess the curative properties of fucoxanthin against the lipopolysaccharides (LPS)‑induced acute lung injury in the experimental animal model. Results: The fucoxanthin treatment followed by the LPS administration was exhibited the marked reduction in the wet‑to‑dry ratio of the lungs, reduced level of infiltration of inflammatory cells in BALF, reduced the enzymatic action of myeloperoxidase in the lungs, reduced the interleukin‑6 (IL‑6), IL‑1 β, and tumor necrosis factor‑alpha levels, possessed the notable suppression and downregulation in the expression of immunoreactivity of inflammatory markers like NF‑κB p65 and decreased the oozing of mucus and the inflammatory cellular infiltration in lung histopathology which is stimulated by the LPS administration. Conclusion: The fucoxanthin was effectively attenuated the LPS‑stimulated acute lung injury in an animal model. Hence, it can be concluded that the fucoxanthin had potent therapeutic properties against the LPS‑stimulated acute lung injury.